Key Highlights
- Rachel Page appointed as Chief Commercial Officer at Veristat.
- Succeeding Cindy Henderson, now Chief Strategy Officer.
- Over 20 years of experience in global health and science commercialization.
- Will oversee commercialization strategy, business development, and client relationships.
- Focus on accelerating the availability of groundbreaking treatments.
Source: Business Wire
Notable Quotes
- “Veristat has a 30-year history of driving innovative approaches that help deliver what are often breakthrough therapies to patients in need. Rachel’s accomplishments and experience empowering people, building commercial organizations, and fostering trusted client relationships demonstrate her ability to successfully lead the execution of our strategic plan.” – Patrick Flanagan, Chief Executive Officer at Veristat
- “I am thrilled to join this dynamic, science-driven team. Veristat is exceptional at facilitating the delivery of crucial therapies and transforming client operations.” – Rachel Page, Chief Commercial Officer (CCO) at Veristat
SoHC's Take
Rachel Page’s appointment as Chief Commercial Officer marks a significant step for Veristat as it continues to strengthen its leadership team. Her extensive experience in global health and science commercialization will be invaluable in enhancing Veristat’s ability to support biopharmaceutical companies. Rachel’s role will be pivotal in driving the company’s strategic initiatives, particularly in the commercialization of innovative therapies. Her leadership is expected to fortify Veristat’s position as a key player in the clinical and regulatory landscape, ensuring the rapid delivery of groundbreaking treatments to patients in need.
